Allogene Therapeutics (NASDAQ:ALLO) Announces Earnings Results

Allogene Therapeutics (NASDAQ:ALLO) posted its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06, Zacks reports.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $1.94 on Friday. The firm’s fifty day moving average price is $1.94 and its 200-day moving average price is $2.32. The stock has a market cap of $406.76 million, a P/E ratio of -1.24 and a beta of 1.02. Allogene Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $4.89.

Insider Activity

In related news, EVP Zachary Roberts sold 27,199 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the transaction, the executive vice president now owns 488,054 shares of the company’s stock, valued at approximately $868,736.12. This trade represents a 5.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now directly owns 250,713 shares in the company, valued at approximately $428,719.23. This represents a 5.55 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 52,710 shares of company stock worth $92,125. 24.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on ALLO. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price objective on shares of Allogene Therapeutics in a research note on Friday. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Friday. Finally, Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a report on Friday. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Allogene Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $9.40.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).